Jently review

What it is

Jently is a clinician-guided telehealth service operated by Jently, LLC at 3 Bedford Ave #153, Brooklyn, New York, with support at care@jently.com, New York governing law and arbitration seated in New York. Prescribing runs through the MD Integrations network of third-party licensed providers and pharmacies. Its published menu is compounded semaglutide from $149 a month and tirzepatide from $199, NAD⁺ therapy as an injectable and NAD⁺ nasal spray each from $119, sermorelin and sermorelin nasal spray each from $119, glutathione injection from $119, and metformin from $39. Care is entirely online, on a monthly subscription.

How it works

Fully online and subscription-based, prescribed through MD Integrations — a third-party network shared across many telehealth brands, which is a standard structure and worth understanding rather than assuming. It means the clinician reviewing your file is not employed by the brand you are buying from; the brand names the network, which is the disclosure that matters. Naming the operating LLC, the Brooklyn address, the governing law and the arbitration seat puts Jently well ahead of the anonymous end of this board on identity. The commercial terms are stated plainly and are worth reading before you subscribe rather than after: the subscription is cancellable at any time through the patient portal, your card is pre-authorised at intake, pending unprocessed orders may be refunded, and there is no refund at all once a consultation has been completed or a prescription dispensed. That last clause is the one to weigh, because it means the decision point is intake, not delivery. Not published: any state list, so eligibility is only confirmed during intake; the compounding pharmacy; or any third-party accreditation. Its footer links to LegitScript's site generally rather than to a verification page for its own domain, which is not the same as being certified. There is no lab work in the default path.

Pricing transparency

The strongest pricing disclosure in this batch, and correctly denominated. Sermorelin, sermorelin nasal spray and glutathione injection are each published "as low as $119/mo", the same rate as NAD⁺ injectable and NAD⁺ nasal spray, with compounded semaglutide from $149 and tirzepatide from $199 and metformin from $39. A per-month figure for the actual molecule, published on the homepage, is what this board almost never gets — and it means you can compare Jently against a competitor without first working out what a vial is meant to cover. Two qualifications. "As low as" is an entry rate, so confirm the price for the specific formulation, strength and quantity you are prescribed. And the refund position materially affects what those prices mean: because nothing is refundable once a consult is completed or a prescription dispensed, the money is committed earlier than the delivery date suggests. Ask what happens if a provider declines to prescribe after you have paid, and get the answer before intake.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Jently states its products are compounded but does not name the compounding pharmacy, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. It is also not LegitScript-certified — its footer links to LegitScript's general site rather than to a verification for its own domain, which is a distinction worth drawing since a certified competitor's badge resolves to a page naming the domain. On the evidence, offering a nasal-spray route alongside an injection for both sermorelin and NAD⁺ is a convenience choice, not an evidence one, and neither route has data the other lacks. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism whose long-term human outcome data stays thin, with no controlled trial demonstrating the body-composition, recovery or anti-aging results it is marketed for. Injected and intranasal NAD⁺ have no controlled human outcome trials; the single human intravenous study was a pharmacokinetic pilot finding infused NAD⁺ clears from plasma quickly, and the forms with human trial data are the oral precursors NR and NMN, which raise blood NAD⁺ — a biomarker rather than a benefit. Injectable glutathione has essentially no controlled human outcome evidence. Individual results vary.

Pros and watch-outs

The evidence behind what Jently prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

How Jently compares

A few alternatives worth a look, depending on what you’re optimizing for.

• CoreAge Rx

  Injected or intranasal NAD⁺ at a published price across 50 states

  See CoreAge Rx →
• Telos RX

  Choice of GLP-1 formats, including needle-free sublingual tirzepatide

  See Telos RX →
• SLSystem Labs

  NAD⁺ bundled with glutathione, B-12 and sermorelin from one service

  See System Labs →